LUNG

Pulmonx Corp. stock has been impacted by several events in the past six months. The Q4 2025 earnings report showed an 8% increase in worldwide revenue for the full year but a 5% decrease in Q4 revenue. The company refinanced debt and implemented cost restructuring. The Q1 2026 earnings report showed a 9% decrease in worldwide revenue. Pulmonx refinanced its prior CIBC facility with a new $40.0 million senior secured term loan from Perceptive. Insiders have sold more company stock than they have bought. Pulmonx has a consensus "Hold" rating from brokerages. Pulmonx is scheduled to present at the Bank of America Securities 2026 Health Care Conference on May 12, 2026.